Amphastar Pharmaceuticals (AMPH) Gross Profit (2013 - 2026)

Amphastar Pharmaceuticals has reported Gross Profit for 14 years, with the latest figure at $93.5 million in Q2 2026.

• On a quarterly basis, Gross Profit rose 8.07% year-over-year to $93.5 million in Q2 2026; TTM through Jun 2026 was $348.1 million, a 3.39% decrease from a year earlier, with the FY2025 full-year figure at $356.1 million, down 4.76% from the prior year.
• Gross Profit was $93.5 million for Q2 2026 at Amphastar Pharmaceuticals, up from $70.3 million in the prior quarter.
• The five-year high for Gross Profit was $108.4 million in Q3 2023, with the low at $55.8 million in Q1 2022.
• Average Gross Profit over 5 years is $83.0 million, with a median of $86.1 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2026: Gross Profit jumped 85.27% in 2023, then fell 17.51% in 2026.
• Over 5 years, Gross Profit stood at $71.2 million in 2022, then jumped by 35.09% to $96.1 million in 2023, then slipped by 9.87% to $86.6 million in 2024, then dropped by 1.13% to $85.7 million in 2025, then grew by 9.1% to $93.5 million in 2026.
• The last three Gross Profit figures came in at $93.5 million (Q2 2026), $70.3 million (Q1 2026), and $85.7 million (Q4 2025), per Business Quant data.